Identification and Characterization of Fenofibrate-Induced Liver Injury
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BackgroundFenofibrate is a commonly used hypolipidemic associated with rare instances of hepatotoxicity, and routine liver biochemistry monitoring is recommended.AimsThe aim of this study is to describe the presenting clinical features, liver histopathology, and outcomes of 7 cases of acute liver injury associated with fenofibrate.MethodsAll cases of definite, very likely, and probable drug-induced liver injury (DILI) attributed to fenofibrate enrolled in the DILI Network study between 2004 and 2015 were reviewed.ResultsAmong 1229 patients with confirmed DILI, 7 cases (0.6%) were attributed to fenofibrate. The median age was 43 (range 37–61) years, and latency to onset was short (5–8 weeks) in 4 patients but more prolonged (18–56 weeks) in the rest. Laboratory results at presentation showed hepatocellular, mixed, and cholestatic injury, but 6 cases presented with jaundice. No patient had undergone routine monitoring. Four patients required hospitalization and 2 in whom drug discontinuation was delayed had a severe outcome, 1 undergoing liver transplantation, and 1 developing chronic injury and death. Liver biopsy was available in 4 patients and showed diverse injury patterns. Genetic studies showed the presence of the rare HLA-A*33:01 in 3 patients (43 vs. 1% in control populations). The causality scores were highly likely in 5 and probable in 2.ConclusionsLiver injury after fenofibrate exposure occurs with variable latency, enzyme elevation, and histology. Although most cases are self-limited, severe injury and mortality can occur, particularly if drug withdrawal is delayed. Jaundice or abnormal laboratory tests during fenofibrate therapy should trigger prompt discontinuation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493
Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009) · Drug Safety · doi:10.2165/00002018-200932010-00005 · Cited by 486
Self-citationCheung, A. C., Lapointe‐Shaw, L., Kowgier, M., Meza‐Cardona, J., Hirschfield, G. M., Janssen, H. L. A., & Feld, J. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13465 · Cited by 139
Hegade, V. S., Khanna, A., Walker, L. J., Wong, L.-L., Dyson, J. K., & Jones, D. E. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4250-y · Cited by 86 · cited 1×
“This finding has led to studies investigating the role of fenofibrate in PBC where activation of PPAR-a has beneficial effects by down-regulating multiple enzymes involved in the synthesis of toxic bile acids [14, 15].”
Background
Cited by
Drug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
Self-citationPrimary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., Ishibashi, S., & on behalf of the K-877 Study Group (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.44412 · Cited by 136
Drug-induced liver injury: Highlights of the recent literature
Real, M., Barnhill, M. S., Higley, C., Rosenberg, J., & Lewis, J. H. (2019) · Drug Safety · doi:10.1007/s40264-018-0743-2 · Cited by 103
Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate
Wang, H., Li, H., Zhou, Y., Liu, J., Wang, F., & Zhao, Q. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612825666191126102943 · Cited by 11
Metadata
- Authors
- Ahmad, J., Odin, J. A., Hayashi, P. H., Chalasani, N., Fontana, R. J., Barnhart, H., Cirulli, E. T., Kleiner, D. E., & Hoofnagle, J. H.
- Venue
- Digestive Diseases and Sciences
- Published
- 2017-11-08
- Volume
- 62
- Issue
- 12
- Pages
- 3596-3604
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2767602680
- Cited by
- 69
- References
- 6
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.